|
Is the biotechs the end of the line? Or do the benefits of cheap money to these companies accrue to anyone but the investors and the insiders? Notably, I was looking at medical research outsourcers, or CCROs, such as Covance (CVD), Kendle (KNDL), Quintiles (QTRN), Parexel (PRXL), and Albany Molecular (AMRI)? AMRI looks to be in the best position, both fundamentally and technically. As disclosure, don't currently own any of the above. On the other hand, from the memory of 1992, the cheap money can flow out just as quick. |
